Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19

NCT04457726 is registered in ClinicalTrials.gov with KK Women's and Children's Hospital as lead sponsor.

NCT NCT04457726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04457726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
Lead sponsor
KK Women's and Children's Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2020
Completion date
December 31, 2022
Enrollment
18 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19